Gentech, a subsidiary of Roche, announced on April 18, local time, that the US Food and Drug Administration (FDA) approved Roche's Alecensa for adjuvant treatment of patients with anaplastic lymphoma kinase (ALK) -positive non-small cell lung cancer (NSCLC) after tumor resection. The phase III study showed that compared with chemotherapy, Alecensa reduced the risk of disease recurrence or death by 76%. According to the press release, alecensA is the first ALK inhibitor approved to treat patients with early-stage ALK-positive NSCLC whose tumors have been surgically removed.
罗氏抗癌辅助疗法Alecensa获美国FDA批准
Roche's anticancer adjuvant therapy Alecensa approved by US FDA
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.